Researchers connect a specific protein to head and neck cancers

March 17, 2011
Oral squamous cell carcinoma expressing the protein SIRT3 is green, the nucleus is blue and the mitochondria are red.

(PhysOrg.com) -- The discovery that a certain protein is over-expressed in patients with oral cancer may give new treatment hope to people suffering from the particularly aggressive, localized forms of head and neck cancer.

Researchers at the University of Michigan School of Dentistry found that when they inhibited the expression of that protein, called SIRT3 or Sirtuin-3, in oral in a petri dish, the cells did not proliferate and more of them died.

Further, when researchers suppressed the in the cancer cells and combined that with radiation or treatment, the prohibitive effect on cancer cells was even greater, said Yvonne Kapila, associate professor of dentistry and lead author of the study.

Mice that were injected with SIRT3-inhibited oral cancer cells had about a 75 percent reduction in tumors compared to the mice injected with regular oral cancer cells, said Kapila, whose research team began looking at the Sirtuin group of proteins because some studies suggest they are key regulators for cell integrity and survival.

"We thought that maybe cancer cells, because they are very crafty, may also use one of these proteins to their advantage to extend their own survival," Kapila said. "With oral cancer, often the problem is the difficulty of early detection, thus when diagnosed at a late stage the cancer becomes very aggressive. If one can find a way to tailor treatments to those aggressive situations obviously you have a far better case of survival."

She added that oral cancer survival rates haven't changed in decades, so there's a great desire in the scientific community to find more effective treatments.

is the eighth most common cancer worldwide, and oral squamous cell accounts for 90 percent of all malignancies. The five-year survival rate for patients with oral is 34 percent to 62.9 percent, according to the study.

Kapila said some research has shown that SIRT1 and SIRT3 proteins may suppress, rather than support, tumor growth, so it's important to remember that each case is different.

"If people do find that in breast cancer it's a suppressor and we go in and treat patients with an additional suppression of SIRT3, we may do more harm than good," Kapila said.

Kapila stressed that the results are very preliminary.

"This is very much still in the lab," she said. "We are nowhere near having any kind of treatment at this point."

The next step is to look at the SIRT3 in larger animals and then proceed to human trials.

Related Stories

Recommended for you

One in five young colon cancer patients have genetic link

December 13, 2017
As doctors grapple with increasing rates of colorectal cancers in young people, new research from the University of Michigan may offer some insight into how the disease developed and how to prevent further cancers. Researchers ...

New strategy for unleashing cancer-fighting power of p53 gene

December 13, 2017
Tumor protein p53 is one of the most critical determinants of the fate of cancer cells, as it can determine whether a cell lives or dies in response to stress. In a new study published today in the journal Nature Communications, ...

Researchers develop test that can diagnose two cancer types

December 12, 2017
A blood test using infrared spectroscopy can be used to diagnose two types of cancer, lymphoma and melanoma, according to a study led by Georgia State University.

Cancer-causing mutation suppresses immune system around tumours

December 12, 2017
Mutations in 'Ras' genes, which drive 25% of human cancers by causing tumour cells to grow, multiply and spread, can also protect cancer cells from the immune system, finds a new study from the Francis Crick Institute and ...

Atoh1, a potential Achilles' heel of Sonic Hedgehog medulloblastoma

December 12, 2017
Medulloblastoma is the most common type of solid brain tumor in children. Current treatments offer limited success and may leave patients with severe neurological side effects, including psychiatric disorders, growth retardation ...

MRI scans predict patients' ability to fight the spread of cancer

December 12, 2017
A simple, non-invasive procedure that can indicate how long patients with cancer that has spread to the brain might survive and whether they are likely to respond to immunotherapy has been developed by researchers in Liverpool.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.